Home Cart Sign in  
Chemical Structure| 1029317-21-2 Chemical Structure| 1029317-21-2

Structure of PF-4191834
CAS No.: 1029317-21-2

Chemical Structure| 1029317-21-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PF-4191834 is a non-iron-chelating and non-redox 5-lipoxygenase (5-LOX) inhibitor (IC50=229 nM) with ~300-fold selectivity over 12-LOX and 15-LOX. It lacks cyclooxygenase activity and is studied for inflammation and pain.

Synonyms: PF-04191834

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PF-4191834

CAS No. :1029317-21-2
Formula : C22H23N3O2S
M.W : 393.50
SMILES Code : CN1N=CC=C1C2=CC=C(C=C2)SC3=CC=CC(C4(CCOCC4)C(N)=O)=C3
Synonyms :
PF-04191834
MDL No. :MFCD18382581

Safety of PF-4191834

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01064804 Asthma COMPLETED 2025-11-09 Pfizer Investigational Site, B... More >>ruxelles, 1070, Belgium Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.54mL

0.51mL

0.25mL

12.71mL

2.54mL

1.27mL

25.41mL

5.08mL

2.54mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories